Brought to you by:
InspireMD and NAMSA to partner on CGUARDIANS II pivotal clinical trial
InspireMD and North American Science Associates (NAMSA) today announced that, pursuant to a previously announced strategic outsourcing partnership, the companies are working together to conduct the CGUARDIANS II pivotal study of InspireMD’s CGuard Prime 80cm carotid stent system for use in…
ROADSTER 3 provides key evidence that ‘goes beyond registry data’ on TCAR-related stroke rates
Thirty-day results from the ROADSTER 3 study have demonstrated that transcarotid artery revascularization (TCAR) is a safe and effective approach in patients who are deemed to be standard risk for experiencing adverse events related to carotid endarterectomy (CEA). These findings…
Novel measure suggests 20% of elective carotid revascularizations fail to achieve a textbook outcome
One in five patients failed to achieve a textbook outcome after undergoing carotid endarterectomy (CEA), transcarotid artery revascularization (TCAR) or transfemoral carotid artery stenting (TF-CAS), a Vascular Quality Initiative (VQI) analysis that tested a novel, patient-centric textbook outcome metric found.…
InspireMD receives IDE approval from FDA for CGUARDIANS II pivotal trial
InspireMD has announced that the Food and Drug Administration (FDA) approval of the company’s investigational device exemption (IDE) application to initiate the CGUARDIANS II pivotal study of its CGuard Prime 80cm carotid stent system during transcarotid artery revascularization (TCAR) procedures.…
Boston Scientific completes acquisition of Silk Road Medical
Boston Scientific announced the close of its acquisition of Silk Road Medical, the company behind transcarotid artery revascularization (TCAR). “The integration of the TCAR platform into our portfolio means we can offer a treatment option for patients suffering from carotid artery disease that…
Silk Road celebrates milestone of 100,000 TCAR procedures
Silk Road Medical has announced the milestone of more than 100,000 transcarotid artery revascularisation (TCAR) procedures having been performed to date. “A growing number of patients come to us looking for a solution that is minimally invasive and requires less…
CEA and TCAR should be ‘first-line’ interventions for weekend carotid revascularization, researchers advise
Patients who undergo carotid revascularization at the weekend have increased odds of complications and mortality, with transfemoral carotid artery stenting (TFCAS) posing the highest risk and transcarotid artery revascularization (TCAR) the lowest, compared to carotid endarterectomy (CEA). This is one…
The top 10 most popular Vascular Specialist stories of June 2024
In June, the most read stories from Vascular Specialist included key reports from the 2024 Vascular Annual Meeting (VAM; June 19–22) covering TEVAR, CEA vs TCAR, PAD and CFA-reintervention, among others; Linda Harris’ placement as SVS vice president; the relationship…
Patient selection may explain ‘counterintuitive’ relationship between carotid stenting volume and outcomes in new study
High stroke and death rates relating to carotid stenting in the Pacific Northwest may be driven by the selection of high-risk patients with less than 80% stenosis, and reducing the frequency of stenting in this high-risk group—along with better adherence…
TCAR and endarterectomy both ‘reasonable’ but stenting linked to worse outcomes in kidney disease patients
A study examining outcomes between different carotid revascularisation procedures has concluded that transcarotid artery revascularisation (TCAR) and carotid endarterectomy (CEA) both represent a “reasonable choice” in severe chronic kidney disease (CKD) and haemodialysis patients—but transfemoral carotid artery stenting (TF-CAS) appears more likely to result…